Heart disease biotech Kardigan raises $400M in IPO

Kardigan, a clinical-stage cardiac disease drugmaker, raised about $400 million in its IPO.

By the numbers: The IPO priced below the company's Series B price of $21.37 per share, a roughly 25% discount, per the S-1.